The Quality Overall Summary (QOS) is an element of a drug marketing application that provides a substantially condensed summary of the quality-related data provided in the submission. Regulators can use the QOS to more effectively assess applications and more rapidly comprehend the quality information in the context of patient risk, including the proposed control strategy and any other planned steps to mitigate that risk. Patients benefit from the greater assessment efficiency by having improved access to drugs that are designed and manufactured to consistently and safely fulfill claims in the label.
News & Trends
Procurar
Recentes
- Update to EU GMP Guidelines – Revised Annex 19 on Reference and Retention Samples
- FARMACOVIGILÂNCIA nível avançado : Formação completa con casos práticos
- FDA DRAFT GUIDANCE :Demonstrating Substantial Evidence of Effectiveness for Human Drug and Biological Products
- European Biotech Act: Positioning EU as Biotech Powerhouse
- CIOMS Glossary of ICH Terms and Definitions. Version 10
- Guidance on standardisation for medical devices Appendix: Transition to the ‘EU REP’ symbol in EN ISO 15223-1
- MDCG Position Paper: Management of SS(C)P in EUDAMED after mandatory use
- Commission Implementing Decision amending Implementing Decision (EU) 2021/1195 as regards the harmonised standard for symbols to be used with information to be supplied by the manufacturer